United States Peptide Regulations

The short answer

As of October 2026, no US rule makes a peptide legal to sell just because it carries a "research use only" (RUO) label. The FDA decides whether a product is a drug by its intended use. It reads that intent from the seller's website and marketing. If the evidence points to human use, FDA treats the product as an unapproved new drug, whatever the disclaimer says.

Lawful access for people mostly runs through prescriptions: an FDA-approved peptide drug, or a compounded product from a licensed pharmacy that follows federal compounding rules.

How federal law classifies peptides

US law has no separate legal category for peptides. A peptide meant for use in people is regulated like any other drug under the FD&C Act, the main federal drug law. Selling a new drug across state lines without an approved application violates sections 301(d) and 505(a). That's the charge FDA uses against RUO sellers. Above 40 amino acids, a polypeptide counts as a biological product. Pharmacist-attorney Mark Boesen notes that biologics can't be compounded under section 503A.

Research-use-only labels and 2026 enforcement

FDA set out its position in warning letters this year. On March 31, 2026, it wrote to Gram Peptides about retatrutide and tirzepatide, along with bacteriostatic water. The site's "Research Use Only" disclaimers didn't matter, because its website showed the products were intended for human use.

The August 24, 2026 letter to Peak Performance Peptides covered five peptides (retatrutide, semaglutide, SS-31, PT-141, tesamorelin) plus bacteriostatic water. The product text FDA quoted was mild, with lines such as "Studied for effects on sexual arousal and libido." Selling bacteriostatic water alongside the peptides, FDA said, provided "the means to prepare an injectable drug for human administration."

Then came prison time. On July 30, 2026, a federal judge in Indiana sentenced Paradigm Peptides owner Matthew Kawa to 70 months. According to CBS News, he had pleaded guilty to selling unapproved drugs and illegally importing them, and admitted the company forged laboratory certificates. Prosecutors said six of its "SARM" products contained actual testosterone. CBS called it a rare criminal penalty for a research-label seller.

Imports are under pressure too. Customs and Border Protection (CBP) officers in Cincinnati seized about 5,000 mis-manifested peptide shipments from China between December 2025 and March 2026. Retatrutide and MOTS-c were among the seized peptides. As of October 2026, FDA's Import Alert 66-80 lets border staff detain foreign GLP-1 ingredients without examination unless the maker is on FDA's "Green List."

What this means for buyers

Every letter and case above targets sellers. We found no 2026 federal case against someone who bought peptides only for personal use. That's an observation, not a safe harbor. FDA's personal importation page says importing unapproved drugs is illegal for individuals "in most circumstances." Its staff have limited discretion, mainly for serious conditions with no US treatment, generally up to a three-month supply.

Compounding under 503A and 503B

Compounding pharmacies can sometimes make drugs that have no approved version, which is why the 2026 compounding changes drew so much attention.

503A pharmacies

A 503A pharmacy compounds for an individual patient with a prescription. Under FDA's rules, it may use a bulk ingredient only if one of three things is true. The ingredient has a USP or NF monograph, is part of an FDA-approved drug, or appears on FDA's 503A bulks list. Most peptides pass none of those tests.

While FDA works through nominations, an interim policy sorts nominated substances into categories. FDA doesn't intend to act against compounding with Category 1 substances; Category 2 means it found "significant safety risks." Substances nominated on or after January 7, 2025, aren't placed in any category.

In 2023, FDA put many popular peptides into Category 2. In February 2026, HHS Secretary Robert F. Kennedy Jr. said he expected FDA to make about 14 peptides more accessible. Then things moved:

• April 2026: FDA removed 12 peptides from Category 2 because their nominators withdrew the nominations. BPC-157 and TB-500 (a thymosin beta-4 fragment) were among them. Removal isn't permission. The peptides landed in no category, outside the interim policy that protects only Category 1.
• July 23-24, 2026: FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of seven peptides for the 503A bulks list, against FDA staff advice. The votes were close; BPC-157 passed 8-6-1.
• Since then: A PCAC vote is only advice. Adding a substance to the list takes notice-and-comment rulemaking. As of October 2026, we found no proposed rule or interim enforcement policy for the six.

Even a listed peptide could only come from a licensed pharmacy with a valid prescription. As the law firm LumaLex points out, none of this legalizes consumer sales of RUO products.

503B outsourcing facilities and GLP-1s

503B outsourcing facilities compound in larger batches. FDA says they can use a bulk ingredient only if it's on the 503B bulks list or the finished drug is on FDA's shortage list.

That rule shaped the compounded GLP-1 market. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025. Its grace periods for compounders ended by May 2025. On April 30, 2026, FDA proposed excluding semaglutide from the 503B bulks list, citing "no clinical need." Tirzepatide and liraglutide got the same proposal. As of October 2026, we found no final decision.

503A pharmacies face a different limit: they can't regularly make "essentially a copy" of a commercially available drug. In an April 1, 2026 update, FDA said semaglutide with added vitamin B12 may still count as a copy. It generally won't act on four or fewer such prescriptions a month. In March 2026 it also sent 30 warning letters to telehealth companies whose ads implied compounded GLP-1s matched approved drugs.

Prescription peptides

Several peptides are FDA-approved drugs, available by prescription for specific conditions:

• Tesamorelin is approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. A new formulation, Egrifta WR, was approved in 2025, and its label says it isn't indicated for weight loss. Our tesamorelin profile covers the trial data.
• Elamipretide (SS-31) received accelerated approval as Forzinity on September 19, 2025, for Barth syndrome in patients weighing at least 30 kg. FDA requires a confirmatory trial.
• GLP-1 drugs such as semaglutide and tirzepatide are approved for type 2 diabetes and chronic weight management.

An approved version doesn't make a research vial of the same compound legal, or equivalent. The August 2026 warning letter named SS-31 and tesamorelin sold under RUO labels. Research vials haven't been checked by FDA for identity or sterility.

Human growth hormone is a special case

HGH has its own criminal provision in the FD&C Act, 21 U.S.C. 333(e). Knowingly distributing HGH, or possessing it with intent to distribute, carries up to five years in prison. The exception is treatment of a disease or recognized medical condition, where FDA has authorized the use and a physician has ordered it. The statute defines HGH as somatropin or somatrem, or an analogue of either.

This is an FD&C Act penalty, not a DEA schedule. Peptides that prompt the body to release its own growth hormone are different molecules. Ipamorelin is one example, and we found no case applying section 333(e) to such peptides.

State rules

States regulate pharmacies and compounding on their own, and Boesen notes that several keep their own restricted-substance lists. A peptide that becomes federally compoundable could still be unavailable in some states. We didn't review individual state laws for this update.

Rules for specific groups

• Service members: the Department of Defense bars use of any ingredient in its prohibited dietary supplement database, and it treats unapproved drugs in supplements as prohibited too. As of October 2026, the database was last updated on September 3, 2026.
• Tested athletes: WADA's 2026 Prohibited List applies regardless of FDA status. Our sports-rules pages cover where each peptide sits.

What to watch next

• Whether FDA proposes a rule, or interim Category 1 placement, for the six peptides the PCAC backed.
• The second PCAC review (LL-37, dihexa, melanotan II, PEG-MGF, GHK-Cu), planned before the end of February 2027.
• FDA's final decision on keeping GLP-1s off the 503B bulks list.
• Further warning letters and prosecutions aimed at RUO sellers.

Other regions have their own pages, such as European Union rules and Australia and New Zealand rules. The regional regulations hub collects them all.